Labels The Issue For Viatris Again As It Recalls Insulin Glargine Biosimilar
Bernstein: Recall Could ‘Spell Problem’ For Biocon-Manufactured Product
A further voluntary recall for Viatris’ insulin glargine biosimilar, this time for one of its recently launched interchangeable products, because of missing labels may draw unwanted interest from the US FDA, a leading analyst has warned.
